175 related articles for article (PubMed ID: 36106577)
101. Improved HDAC Inhibition, Stronger Cytotoxic Effect and Higher Selectivity against Leukemias and Lymphomas of Novel, Tricyclic Vorinostat Analogues.
Bieszczad B; Garbicz D; Świtalska M; Dudek MK; Warszycki D; Wietrzyk J; Grzesiuk E; Mieczkowski A
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577551
[TBL] [Abstract][Full Text] [Related]
102. Effect of vorinostat on protein expression
Tang M; Hattori Y
Biomed Rep; 2024 Jul; 21(1):105. PubMed ID: 38868527
[TBL] [Abstract][Full Text] [Related]
103. Identification of druggable genes for multiple myeloma based on genomic information.
Satria RD; Irham LM; Adikusuma W; Puspitaningrum AN; Afief AR; Khair RE; Septama AW
Genomics Inform; 2023 Sep; 21(3):e31. PubMed ID: 37813627
[TBL] [Abstract][Full Text] [Related]
104. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
[TBL] [Abstract][Full Text] [Related]
105. Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity.
Khetmalis YM; Fathima A; Schweipert M; Debarnot C; Bandaru NVMR; Murugesan S; Jamma T; Meyer-Almes FJ; Sekhar KVGC
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446224
[TBL] [Abstract][Full Text] [Related]
106. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
Duvic M; Vu J
Expert Opin Investig Drugs; 2007 Jul; 16(7):1111-20. PubMed ID: 17594194
[TBL] [Abstract][Full Text] [Related]
107. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
108. Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma.
Watanabe E; Yokoi A; Yoshida K; Sugiyama M; Kitagawa M; Nishino K; Yamamoto E; Niimi K; Yamamoto Y; Kajiyama H
Cancer Med; 2023 Feb; 12(4):4543-4556. PubMed ID: 36106577
[TBL] [Abstract][Full Text] [Related]
109. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
110. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
111. Melatonin-vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat.
Helmi YY; Papenkordt N; Rennar G; Gbahou F; El-Hady AK; Labani N; Schmidtkunz K; Boettcher S; Jockers R; Abdel-Halim M; Jung M; Zlotos DP
Arch Pharm (Weinheim); 2023 Sep; 356(9):e2300149. PubMed ID: 37339785
[TBL] [Abstract][Full Text] [Related]
112. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
113. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
[TBL] [Abstract][Full Text] [Related]
114. Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in
Zhang T; Sun B; Zhong C; Xu K; Wang Z; Hofman P; Nagano T; Legras A; Breadner D; Ricciuti B; Divisi D; Schmid RA; Peng RW; Yang H; Yao F
Transl Lung Cancer Res; 2021 Apr; 10(4):1857-1872. PubMed ID: 34012798
[TBL] [Abstract][Full Text] [Related]
115. Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis.
Wang X; Liu K; Gong H; Li D; Chu W; Zhao D; Wang X; Xu D
Toxicol Appl Pharmacol; 2021 Jan; 410():115363. PubMed ID: 33290780
[TBL] [Abstract][Full Text] [Related]
116.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
117.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
